AstraZeneca has made huge moves in the 2nd half of 2017, particularly with respect to lung cancer therapy. The company has quickly gone from secondary consideration to the front of the line in multiple areas.
I have always been a fan of medicines mammoth AstraZeneca (LSE: AZN), and I'm not ashamed to admit it. Share price trouble is part and parcel of investing in pharmaceuticals and the Cambridge company has been no stranger to this in recent months.
LONDON (Alliance News) - Hutchison China MediTech Ltd said Tuesday it and AstraZeneca PLC presented safety and clinical data of combinations of savolitinib at the World Conference on Lung Cancer in Yokohama, Japan.
What a rollercoaster few months it's been for FTSE 100 pharmaceutical giant Astrazeneca (LSE: AZN). After a decent rise over the first half of 2017, the share price plummeted in late July after the company reported disappointing trial outcomes relating ...